54 results about "Receptor specificity" patented technology

The invention relates to the technical field of biological medicine, in particular to a functionalized targeted liposome and application thereof, and the functionalized targeted liposome comprises lipid and a targeted ligand, wherein the targeting ligand can be specifically combined with a TREM2 receptor. According to the lipidosome, the targeting ligand can be specifically combined with the TREM2 receptor, accurate targeting of cells with the surface containing the TREM2 receptor is achieved, it is ensured that the cells directly act on target cells, the accuracy of a delivered substance is further improved, and the lipidosome has the advantages of being targeting, high in stability, small in side effect and high in bioavailability. The functionalized targeted liposome can be applied to the development of drug carriers, pharmaceutical compositions and the like, and has wide application prospects, for example, the liposome is dynamically connected with hydrogel molecules through a borate bond to prepare a hydrogel pharmaceutical composition containing the functionalized targeted liposome, and the application prospect is wide. The liposome disclosed by the invention can respond to an inflammatory environment according to pH and ROS changes of a surrounding environment to release the liposome disclosed by the invention, targets cells with TREM2 receptors on the surfaces, namely microglial cells (with the TREM2 receptors on the surfaces) by virtue of the target ligands exposed on the surfaces, regulates the polarization state of the cells, inhibits the polarization of the cells to a pro-inflammatory M1 type and promotes the polarization of the cells to an anti-inflammatory M2 type, so that the anti-inflammatory effect of the liposome is improved. Therefore, the local microenvironment of the spinal cord injury part is improved, and nerve regeneration is promoted.

The invention provides a TOLL-like receptor 7 (TLR7) specific antagonist as well as a preparation method and application of the TOLL-like receptor 7 (TLR7) specific antagonist. The TLR7 antagonist has a structure as shown in a formula (I) or a formula (II), has outstanding TLR7 antagonistic activity and selectivity, and is expected to be applied to prevention and treatment of related diseases.

The invention discloses CCL2, a receptor specific binding polypeptide thereof and application of the receptor specific binding polypeptide in prevention and treatment of cholestatic liver diseases, and relates to the technical field of biological medicines. The CCL2 and the receptor specific binding polypeptide thereof, which are screened by a molecular simulation technology, can be specifically bound with a key molecule CCL2 for inducing diseases and a plurality of receptors thereof in a cholestatic liver disease occurrence process, so that liver function indexes are recovered; the traditional Chinese medicine composition can be used for relieving liver pathological injury, including inhibiting bile duct hyperplasia, relieving portal vein inflammatory response and relieving portal vein fibrosis, so that the pathological development process of fibrosis and inflammation caused by the liver injury is blocked.

The invention belongs to the crossing field of marine biotechnology and bioinformatics, and particularly relates to a method for high-throughput identification of natural functional oligopeptides. At present, bottlenecks still exist in development and application of various functional oligopeptides such as penetrating peptides and antibacterial peptides in non-model species, and the high adaptability of the existing functional oligopeptides in complex and diverse non-model organisms is limited mainly due to differences (amino acid preference and receptor specificity) among species. Therefore, the invention provides a method for high-throughput identification of functional oligopeptides from natural sequences of organisms by means of machine learning. According to the method, based on a biological natural protein sequence, an oligopeptide sequence set meeting a preset length condition is generated through a sliding window strategy system, a deep machine learning model is utilized to perform high-throughput functional prediction on the oligopeptide sequence, and on the basis of performing'interruption-prediction-re-comparison 'on existing functional oligopeptides, the functional oligopeptide sequence set meeting the preset length condition is obtained. The comparison threshold value for accurately identifying the functional oligopeptide can be determined, and the natural functional oligopeptide existing in the protein sequence can be effectively identified based on the threshold value. The functional oligopeptide obtained by the method has strict screening of physicochemical properties of a machine learning model and high-adaptability biological characteristics formed in species evolution. According to the method, the direct application capability of the functional oligopeptide in non-model species is remarkably improved, and an accurate and high-throughput technical means is provided for efficient development and application of the functional oligopeptide in non-model organisms.

The invention discloses an odor receptor gene SinfOR21 of sesamia inferens and application of the odor receptor gene SinfOR21. Belongs to the technical field of biology. According to the invention, sex pheromones of Zhejiang and Guangdong sesamia inferens strains and expression and functional verification of olfaction receptor genes of the sesamia inferens are identified and compared. The method comprises the following steps: firstly, identifying pheromone mixtures with region specificity, and verifying the behavior effectiveness of the pheromone mixtures in field trials; through transcriptome and function analysis, it is proved that a SinfOR21 receptor of the Zhejiang strain is specifically combined with Z11-16: OH, and a homologous receptor of the Guangdong strain does not have the function. And determining that the sex pheromone mixture of the sesamia inferens should be composed of Z11-16: Ac, 16: Ac and Z11-16: Ald. Different from reported sex pheromone mixtures of sesamia zhejiangensis, the sex pheromone mixture of sesamia zhejiangensis is composed of Z11-16: Ac, Z11-16: OH and Z11-16: Ald.

The invention relates to the technical field of biological medicine, and discloses a ROS / pH dual-response carrier-based drug delivery system, which comprises an inner core, a response layer and a targeting layer, wherein the inner core is composed of a poly (beta-amino ester) polymer, and the poly (beta-amino ester) polymer is used for coating a drug; the response layer is composed of an ROS sensitive connecting arm wrapping the outer side of the poly (beta-amino ester) polymer; the targeting layer is composed of heart targeting peptide, and the heart targeting peptide is covalently coupled to the inner side of the ROS sensitive connecting arm; according to the present invention, the cardiac targeting peptide is used for the specific binding with the myocardial cell membrane surface receptor, and the ROS sensitive connecting arm is broken in the high ROS environment, such that the poly (beta-amino ester) polymer is dissolved in the lysosome acid environment so as to pertinently release the drug, and the preparation method and the application thereof are provided. Targeted delivery and targeted release of the drug delivery system are achieved, and the drug delivery system can serve as a drug carrier to be applied to treatment of metabolic cardiovascular diseases.

The present invention discloses a somatostatin type 2 receptor inhibitor, its radionuclide complex, preparation method and application. The somatostatin type 2 receptor inhibitor has a structure shown in the following formula I: wherein, n is a natural number selected from 1 to 7. Based on the somatostatin type 2 receptor inhibitor, the complexes formed by labeling <supgt;99m< / supgt;Tc or <supgt;188< / supgt;Re can be respectively used for specific SPECT / CT imaging of somatostatin type 2 receptors or the treatment of neuroendocrine tumors. The complexes have the characteristics of high labeling rate, good stability and good tumor tissue targeting, providing a new idea for the integrated diagnosis and treatment of neuroendocrine tumors.

The invention provides a system that comprises pharmaceutical agents for use in immunotherapy for reducing the side-effects of an antigen-recognizing receptor against antigen-expressing non-target cells in an individual. The system includes an antigen-recognizing receptor that specifically recognizes an antigen on target cells and at least on one hematopoietic cell type in the individual. The antigen-recognizing receptor is exemplified by chimeric antigen receptors (CAR) be expressed on the surface of an immune effector cells. The system also includes hematopoietic cells resistant to recognition of the same antigen by the antigen-recognizing receptor.

The invention discloses a pilose antler active peptide and application thereof in anti-inflammation, anti-oxidation and anti-aging, and belongs to the technical field of biology. According to the invention, the brand-new active peptide SPLASDLDL screened out from pilose antler for the first time is utilized, and competitive inhibition on TNFR1 is realized through the characteristic that the brand-new active peptide SPLASDLDL is specifically combined with a TNFR1 receptor. A constructed sertoli cell senescence model proves that the polypeptide has anti-inflammatory, anti-oxidation and anti-senescence effects. The invention successfully solves the technical problem that in the prior art, the competitive inhibition TNFR1 targeting peptide cannot be found from pilose antler and the action mechanism of the TNFR1 targeting peptide cannot be clarified, and provides the action mechanism and scientific basis for developing novel anti-inflammatory and anti-aging drugs derived from natural products.

The application discloses a dry-cured ham source oligopeptide and application thereof. The dry-cured ham source oligopeptide comprises at least one of the following amino acid sequences: ELIDQDARDLY, YHEHRSDLN, YKATEPVIAF, INKVEELKKKY and GEKLKRQKY. The dry-cured ham source oligopeptide is applied to preparation of a drug for treating a glycolipid metabolism disorder disease. The extracted and verified oligopeptide can be specifically combined with an AdipoR2 receptor, has stronger glycolipid metabolism regulation activity than a KRQKYD polypeptide, can significantly improve various glycolipid metabolism disorder diseases, and has a good application prospect.

The present technology provides compositions and methods for modulating T Cell Receptor (TCR) specificity as well as methods for treating cancer in a subject in need thereof. The present disclosure provides engineered cytotoxic T cells comprising a TCR and / or nucleic acid encoding the TCR and a mutant CD8 alpha polypeptide and / or nucleic acid encoding the mutant CD8 alpha polypeptide.

The present disclosure relates to a tumor necrosis factor receptor 2 (TNFR2) agonist polypeptide comprising (i) a TNFR2 binding domain comprising three TNF homologous domains (THDs) that specifically bind to TNFR2; and (ii) an Fc domain. The present disclosure also relates to TNFR2 agonists for use in the treatment and / or prevention of e.g. Chronic pain or multiple sclerosis.

The present disclosure provides a class of compounds comprising a ligand moiety that specifically binds to a cell surface mannose-6-phosphate receptor (M6PR). The M6PR binding compound can trigger the receptor to internalize the bound compound into the cell. Ligand moieties of the present disclosure may be linked to a variety of moieties of interest without affecting specific binding to M6PR and its function. Also provided are compounds that are conjugates of a ligand moiety linked to a biomolecule, such as an antibody, that can utilize a cellular pathway to remove a specific target protein from the cell surface or extracellular environment. For example, the conjugates described herein can isolate and / or degrade a target molecule of interest in the lysosome of a cell. Methods of targeting proteins for isolation and / or lysosomal degradation using the conjugates are also provided.

The invention includes a chimeric autoantibody receptor (CAAR) specific for anti-acetylcholine receptor (AChR) B cell receptor (BCR), compositions comprising the CAAR, polynucleotides encoding the CAAR, vectors comprising a polynucleotide encoding the CAAR, and recombinant cells, e.g., T cells comprising the CAAR.

The invention relates to a CCR5 binding protein with a protein de novo design and an application method of the CCR5 binding protein in HIV (Human Immunodeficiency Virus) inhibition. By adopting an artificial intelligence algorithm (such as RFdiversity, ProteinMPNN-FastRelax and AlphaFold2) and a molecular dynamics simulation technology, the invention provides an innovative de novo design method, and the protein molecule specifically bound with the CCR5 receptor can be accurately designed. The designed CCR5 binding proteins not only can effectively prevent the combination of HIV-1gp120 and CCR5 receptors, but also can inhibit the invasion of HIV viruses in the early stage of infection, and overcome the problems of drug resistance and side effects in the existing treatment methods. According to the design method, the production cost is reduced, the protein production efficiency is improved, a treatment strategy with a wide clinical application prospect is provided for HIV prevention and treatment, and remarkable economic value and market potential are achieved.

The invention discloses a polypeptide for promoting collagen synthesis and application thereof. The polypeptide capable of promoting collagen synthesis is specifically combined with a receptor TbetaR II to regulate collagen synthesis in fibroblasts, and is a TGF-beta mimic peptide analogue. And the TB2 has a proliferation effect on BALB / 3T3 cells. The TB2 can promote the expression of collagen related factors Collagen I, Collagen III, Smad3 and MAPK, and has the effects of promoting cell migration and promoting wound healing. Therefore, the polypeptide for promoting collagen synthesis provided by the invention can be used for preparing a preparation for promoting cell proliferation or collagen generation.

Described is the use of a first antibody molecule that specifically binds to Fc [gamma] Rllb through its Fab region but lacks an Fc region or through its Fc region has reduced binding to the Fc [gamma] receptor for use in the treatment of Fc [gamma] Rllb negative cancer in a patient in combination with a second antibody molecule, and a second antibody molecule that specifically binds to a receptor present on an immune cell that inhibits anti-cancer immunity, the second antibody molecule having an Fc region that binds to at least one activated Fc [gamma] receptor, and wherein the binding of the second antibody molecule to the receptor on the immune cell causes depletion and / or deactivation of the immune cell; as well as pharmaceutical compositions and kits comprising these two antibody molecules; and methods of treating cancer using the two antibodies.

The present application provides compositions and methods for increasing safety, selectivity, and efficacy of transduction of human cells, including human long-term repopulating and hematopoietic stem cells (LT-HSC) and human cancer cells, by adenovirus vectors through multiplexed targeting of virus attachment and internalization receptors. Multiplexing targeting Ad vector receptor specificities through the combination of i) restricting fiber-specific attachment receptors, ii) deleting the RGD amino acid motif from the penton base protein, and iii) inserting into Ad penton base protein of peptides that lack the RGD amino acid motif and enable vector interaction with integrin classes expressed on target cells, allows for the improvement of safety, selectivity, and efficacy of vector-mediated transduction of human cells in vitro and after intravenous vector administration in vivo.

Provided is use of an HPCAL1 protein in enhancing cardiac function. The HPCAL1 protein can specifically bind to a recombinant β3-adrenergic receptor, and can be used as a β3-adrenergic receptor antagonist protein. It is found in animal experiments that by intravenously injecting recombinant mouse HPCAL1 with a certain concentration into an ischemia-reperfusion mouse model, the cardiac function of the mice can be effectively improved, and the ejection fraction of the mice is enhanced, indicating that the HPCAL1 protein can be used for enhancing the cardiac function and has potential medicinal value for treating cardiovascular diseases with cardiac function decline. Moreover, the HPCAL1 protein is a class of biomacromolecules with low toxicity, which solves the problem of high hepatic and renal toxicity of small molecule chemical drugs. Therefore, the HPCAL1 protein has relatively high application value.

Some aspects of the disclosure relate to complexes comprising a muscle-targeting agent covalently linked to a molecular payload. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on a muscle cell. In some embodiments, the molecular payload inhibits expression or activity of DUX4. In some embodiments, the molecular payload is an oligonucleotide, such as an antisense oligonucleotide or an RNAi oligonucleotide.

The present application relates to the technical field of biological medicine, in particular to a functionalized targeted liposome and application thereof, comprising: lipids and a targeting ligand; wherein the targeting ligand can specifically bind to a TREM2 receptor. The liposome of the present application can specifically bind to the TREM2 receptor by means of the targeting ligand, realize precise targeting of cells containing the TREM2 receptor on the surface, ensure direct action on target cells, and further improve the precision of delivered substances. The liposome has targeting property, high stability, small side effects, and can be applied to the development of drug carriers, pharmaceutical compositions, etc., and has a wide application prospect. For example, the liposome of the present application is dynamically connected with a hydrogel molecule by a borate ester bond to prepare a hydrogel pharmaceutical composition containing the functionalized targeted liposome of the present application. The hydrogel pharmaceutical composition can release the liposome of the present application according to the change of pH and ROS in the surrounding environment in response to an inflammatory environment, and target cells containing the TREM2 receptor on the surface, i.e. microglial cells (having the TREM2 receptor on the surface), by virtue of the targeting ligand exposed on the surface, and regulate the polarization state of the cells, inhibit the polarization of the cells to the pro-inflammatory M1 type, and promote the polarization of the cells to the anti-inflammatory M2 type, thereby improving the local microenvironment of the spinal cord injury site and promoting nerve regeneration.

The present technology provides compositions and methods for modulating T Cell Receptor (TCR) specificity as well as methods for treating cancer in a subject in need thereof. The present disclosure provides engineered cytotoxic T cells comprising a TCR and / or nucleic acid encoding the TCR and a mutant CD8 alpha polypeptide and / or nucleic acid encoding the mutant CD8 alpha polypeptide.

The invention provides anti-IL2 receptor gamma antigen binding proteins. The present invention relates to antibodies that bind to the anti-IL2 receptor gamma protein and methods of use thereof. The present invention provides antibodies and antigen-binding fragments (e.g., human antibodies) that specifically bind to human IL2 receptor gamma (IL2R gamma). Also provided are methods for using the antibodies and fragments to treat or prevent diseases mediated by IL2R gamma (e.g., graft versus host disease) and methods of making the antibodies and fragments.

The present invention provides isolated T cell receptors (TCRs) that specifically bind to an HLA-displayed cancer testis antigen preferentially expressed antigen in melanoma (FRAME) peptide, as well as therapeutic and diagnostic methods of using those isolated TCRs.

The invention discloses a dry-cured ham source oligopeptide and application thereof. The dry-cured ham source oligopeptide comprises at least one of the following amino acid sequences: ELISDQDARDLY; a YHEHRSDLN, a YHEHRSDL YKATEPVIAF is used as a template; the method comprises the following steps: carrying out INKVEELKKKY; and GEKLKRQKY is used as a reference. The dry-cured ham source oligopeptide is applied to preparation of medicines and health-care foods for treating glycolipid metabolism disorder diseases. The oligopeptide extracted and verified by the invention can be specifically combined with an AdipoR2 receptor, shows stronger glycolipid metabolism regulation activity compared with the existing KRQKYD polypeptide, can obviously improve various glycolipid metabolism disorder diseases, and has a better medical and edible application prospect.

The present invention provides a periodontal microneedle loaded with near-infrared responsive composite bilirubin nanoparticles and a preparation method thereof, which belongs to the technical field of composite materials. In the present invention, bilirubin-gelatin complex nanoparticles have good antioxidant activity and promote macrophage repolarization to M2 by removing ROS; folic acid can specifically bind to FA receptors on the surface of M1 macrophages, giving nanoparticles good M1 macrophage targeting properties and improving the bioavailability of the material; organic-metal coordination supramolecular network coating has both anthocyanin and iron ion properties, showing anti-inflammatory and antioxidant therapeutic effects; at the same time, it has both photothermal properties, can convert near-infrared light energy into thermal energy, and induce M1 macrophage apoptosis. Therefore, the near-infrared responsive composite bilirubin nanoparticles provided by the present invention can reshape the periodontitis immune homeostasis by the dual functions of stimulating M1 macrophage apoptosis through photothermal effect and removing ROS to induce M1 macrophage M2 polarization.

The invention discloses a device suitable for aerosol phase virus-receptor affinity and activity evaluation, an evaluation method and a data analysis method. The device comprises an aerosol generation unit, a bionic artificial cell array unit, an environment control and fixing assembly and an activity evaluation and collection unit. The method is characterized in that through a micro-nano processing and molecular self-assembly technology, a supporting lipid double-layer membrane is constructed on an array substrate, receptor protein is directionally fixed, and a bionic cell interface is formed. When in use, a virus sample is atomized into aerosol and flows through the interface, so that the virus is specifically combined with the receptor; affinity parameters in an aerosol environment can be obtained by combining quantitative detection with viruses and utilizing algorithm model fitting. Meanwhile, the system can directly collect an aerosol sample after action and inoculate cells for culture, so that synchronous verification of virus biological infection activity is realized. The device is easy and convenient to operate and high in universality, and a brand new tool is provided for studying the recognition and infection mechanism of viruses under the real aerosol transmission condition.

Provided is use of an HPCAL1 protein in enhancing cardiac function. The HPCAL1 protein can specifically bind to a recombinant β3-adrenergic receptor, and can be used as a β3-adrenergic receptor antagonist protein. It is found in animal experiments that by intravenously injecting recombinant mouse HPCAL1 with a certain concentration into an ischemia-reperfusion mouse model, the cardiac function of the mice can be effectively improved, and the ejection fraction of the mice is enhanced, indicating that the HPCAL1 protein can be used for enhancing the cardiac function and has potential medicinal value for treating cardiovascular diseases with cardiac function decline. Moreover, the HPCAL1 protein is a class of biomacromolecules with low toxicity, which solves the problem of high hepatic and renal toxicity of small molecule chemical drugs. Therefore, the HPCAL1 protein has relatively high application value.

The invention provides a benzimidazole compound as well as a preparation method, a composition and application thereof. Specifically provided is a compound represented by formula (I) or formula (II) or a pharmaceutically acceptable salt thereof. The compound provided by the invention has one or more of the following advantages: (1) novel structure, (2) good GLP-1 receptor agonistic activity, (3) good metabolic stability, (4) good GLP-1 receptor specificity, and (5) good medicinal safety. # imgabs0 #